SavedAdd your journal

Journals / Abant Tıp Dergisi / 2022 / Cilt: 11 - Sayı: 3

The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure

Düşük Ejeksiyon Fraksiyonu ile Kalp Yetmezliğinde Sakubitril-Valsartanın Faydaları

Lütfü AŞKIN
Okan TANRIVERDİ
Pages
337–336
Publication Date
2022-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In HF patients, sacubitril or valsartan may provide significant benefit.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow.
📊
Key Findings & Data:Sacubitril/valsartan reduces mortality and hospitalization and rehospitalization rates for HF compared with enalapril.
💡
Conclusion & Impact:In HF patients, sacubitril or valsartan may provide significant benefit.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kalp Yetmezliği · Natriüretik Peptit · Sakubitril/Valsartan

Abstract

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Sacubitril/valsartan reduces mortality and hospitalization and rehospitalization rates for HF compared with enalapril. In HF patients, sacubitril or valsartan may provide significant benefit.

Özet

Kalp yetmezliği (KY), perifere yetersiz kan akışı nedeniyle egzersiz kapasitesinin bozulmasının nedenidir. Neprilisin enziminin inhibisyonu yoluyla natriüretik peptit (NP) geliştirmesi, KY' deki terapötik hedeftir. Sakubitril/valsartan, enalapril ile karşılaştırıldığında KY için mortalite ve hastaneye yatış ve yeniden hastaneye yatış oranlarını azaltır. Sakubitril/valsartan KY hastalarında önemli fayda sağlayabilir.

🔖

Cite This Article

AŞKIN, L., TANRIVERDİ, O. (2022). The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure. Abant Tıp Dergisi, Cilt: 11 - Sayı: 3, 337–336. https://ajindex.com/articles/874052

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2021;23:352-80
  2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020;141:e139-e596
  3. D'Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 2017;19:710-7
  4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004
  5. Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol 2017;14:171-86
  6. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med 2019;380:1090
  7. Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772-810
  8. McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol 2021;37:531-46
  9. Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, et al. Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499. 10- de Diego C, González-Torres L, Núñez JM, Centurión Inda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm 2018;1